In a wave of programming shifts at CBS, the network drama Watson has concluded after just two seasons, leaving fans with unresolved storylines as it aired its final episode on Sunday, May 3. Starring Morris Chestnut in the title role, the series drew inspiration from Sir Arthur Conan Doyle's iconic Sherlock Holmes tales, reimagining the detective's longtime companion in a modern medical procedural format. The cancellation comes amid broader changes at CBS, where several shows faced uncertain futures while others secured swift renewals.
Watson followed Dr. John Watson six months after the offscreen death of Sherlock Holmes at the hands of his arch-nemesis Moriarty, played by Randall Park. Resuming his medical career, Watson took over as head of a specialized clinic focused on treating rare disorders, blending diagnostic mysteries with personal drama. The first season centered on Watson's intense rivalry with Moriarty, while the second introduced unexpected elements, including appearances by Sherlock Holmes himself, portrayed by Robert Carlyle, despite the character's prior demise.
According to reports from Deadline, CBS's early renewal announcements in January left Watson and the comedy DMV in limbo as the network evaluated its lineup. Decisions hinged on the performance of newer dramas like Marshals and CIA, both of which earned quick second-season pickups. Meanwhile, DMV, which struggled after a promising start with declining multiplatform ratings, was ultimately pulled after one season.
The fate of Watson appeared tied to these shifts, with the show facing obstacles despite initial success. Producers delayed season 2 to slot it into a Monday night position following CIA, a move that coincided with a noticeable dip in viewership. Chestnut, speaking to Us Weekly ahead of the second season, described the series as "a procedural show with the serialized spine," emphasizing its structure of weekly cases intertwined with overarching narratives.
"We have to diagnose and then solve them," Chestnut explained. "But there are also going to be a lot of surprises and a lot of twists and turns that the audience may not expect." He expressed enthusiasm for the evolving storytelling, noting that the absence of Moriarty allowed for deeper exploration of the ensemble cast. "You learn more about the characters on the show," he said. "We spent so much time as Watson was dealing with Moriarty and the loss of Sherlock Holmes that it was pretty much dominating. This year, we get more into the characters. We’re going so much more without Moriarty there. We’re going so much more into character development."
These comments highlighted the show's ambitions to balance episodic medical puzzles with character-driven arcs, but the network's priorities shifted elsewhere. CBS ultimately renewed 12 dramas for the upcoming season, including all four of its freshman entries: Marshals, CIA, Sheriff Country, and Boston Blue. This robust slate signals confidence in the network's newer offerings, even as established series like Watson met an abrupt end.
Among the successes, the Yellowstone spinoff Marshals stands out, securing a second season after its premiere drew 20.6 million viewers within seven days—a figure that marks the most-watched network original series launch without a football lead-in since 2017. Sheriff Country averaged 7.6 million viewers per episode, while Boston Blue pulled in 8 million and dominated Friday nights in total viewership, according to network metrics. The enduring procedural Blue Bloods also contributed to the strong performance, averaging 8 million viewers and consistently winning its time slot.
Looking ahead, CBS has already greenlit two new series for the 2026-27 season: Cupertino, from prolific producers Robert and Michelle King, and Einstein, starring and executive-produced by Matthew Gray Gubler. These additions suggest the network is betting on fresh talent and established creators to refresh its drama portfolio. Deadline reported that the cancellation of DMV paved the way for comedy pilots Eternally Yours and The Tillbrooks—formerly known as Regency—to advance beyond the development stage.
The broader context of CBS's shakeup reflects ongoing challenges in network television, where viewership trends and streaming competition demand constant adaptation. Watson's conclusion, with several plot threads left dangling, underscores the precarious nature of mid-tier performers in a crowded landscape. Fans of the series, who tuned in for its clever nods to Holmes lore and Chestnut's charismatic lead performance, may find solace in the actor's other projects, though no immediate follow-ups have been announced.
Network executives have not publicly detailed the precise metrics behind Watson's axing, but sources indicate that the post-CIA slotting played a role in its softened numbers. Similarly, DMV's early buzz failed to sustain, with delayed ratings revealing a steeper decline than anticipated. In contrast, the rapid renewals for Marshals and its peers highlight CBS's strategy of prioritizing high-impact newcomers over shows that plateaued.
This isn't the first time CBS has navigated such transitions; recent years have seen multiple series face major alterations or outright ends due to similar factors. As the fall lineup takes shape, the network's emphasis on proven hits like Blue Bloods and emerging blockbusters like Marshals points to a future leaning heavily on established franchises and star-driven vehicles. For Watson's creative team, the sudden wrap-up means pivoting to new opportunities, potentially carrying forward the procedural elements that defined the show.
Viewers expressed mixed reactions online following the May 3 finale, with some praising the season's character growth and others lamenting the unresolved Moriarty saga and Holmes teases. Chestnut, in his Us Weekly interview, had hinted at more serialized depth, but the network's decision curtailed those possibilities. As CBS builds toward 2026-27 with Cupertino and Einstein, the landscape continues to evolve, leaving room for Holmes-inspired tales elsewhere—perhaps on streaming platforms hungry for genre blends.
Ultimately, Watson's end exemplifies the high-stakes world of broadcast TV, where even a solid foundation can't always guarantee longevity. With 12 dramas locked in and new pilots advancing, CBS appears poised for stability, though at the cost of series like Watson that offered unique spins on classic archetypes. Fans hoping for closure may revisit the two seasons on demand, while the network charges forward with its revitalized slate.